



Contact:
Bill Enright
President & CEO
Phone: 205-909-3751
Email: enright@vaxin.com

VAXIN HONORED IN TECHJOURNAL SOUTH'S ANNUAL "TECH 50" LIST

VAXIN'S NEEDLE-FREE, CELL CULTURE PRODUCED VACCINE TECHNOLOGY HIGHLIGHTED

Birmingham, Alabama – June 15, 2009 – Vaxin Inc., an emerging vaccine company today announced that it has been named to TechJournal South's 2009 "Tech 50" list, which recognizes the top 50 privately-held technology companies in the southeastern United States. Nominees for the award were judged on several criteria, including technology innovation, management team, marketplace potential and success of execution.

"Vaxin is honored to be recognized as one of the leading technology companies in the southeast," said Bill Enright, President and CEO of Vaxin. "Vaxin is dedicated to developing novel treatments in highly underserved, multi-billion-dollar markets including seasonal influenza, avian influenza, anthrax and Alzheimer's disease. Our growing portfolio of clinical stage vaccine candidates includes needle-free vaccines targeted at these and other currently unmet public health needs. The vaccines are produced utilizing state of the art cell culture technologies to provide extremely rapid response to emerging threats."

About Tech 50 2009:

Sponsored by TechJournal South, Tech 50 is a list of the most innovative high-growth, privately-held companies in the Southeast region. Companies are chosen for inclusion in Tech 50 based on a variety of criteria including, uniqueness of the company's technology, management team, marketplace potential and proven execution success. As an additional qualification for inclusion, all Tech 50 companies must be headquartered in one of the following states: Alabama, Georgia, Florida, Maryland, North Carolina, Virginia/DC, South Carolina or Tennessee. For the complete list of 2009 winners, visit www.tech50.org

About TechJournal South:

Covering the new business economy from Maryland through Florida, TechJournal South reaches the top executives in the top technology industries from biotech to IT. TechJournal South reaches over 50,000 executive readers every month. For further information, visit www.techjournalssouth.com

About Vaxin:

Vaxin Inc. is an emerging clinical stage vaccine company developing needle-free, single dose highly effective vaccines. These molecular vaccines are safely administered either in the nose or on the skin, taking the battle against diseases to the immune system's front lines where the diseases are attacking, rather than injecting the vaccine inside the body where the body's immune response is actually weaker. This also allows Vaxin's vaccines to be mass administered by personnel without sophisticated medical training.

As a vaccine delayed may be a vaccine denied, it is crucial to produce vaccines in a timely manner, especially in the event of a pandemic or bioterrorist attack. The company's technology platform also provides a critical tool for the rapid production of vaccines against influenza, avian influenza, anthrax, and Alzheimer's disease utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin's vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics.

Vaxin's unique technology was developed by Dr. De-chu C. Tang, Vaxin's scientific founder and Vice President of Research. Unlike current vaccines, which typically use a weakened form of the targeted disease, such as the influenza virus, Vaxin's molecular vaccines are created by inserting only a piece of the influenza virus, the antigen, into a benign delivery vehicle. This "Trojan Horse" method increases the safety of the vaccine and virtually eliminates the risk of a vaccine reverting to a disease causing agent. Needle-free, non-replicating, single-dose molecular vaccines also have many other advantages. Patients clearly prefer vaccines which are not injected because there is no fear of needles or the pain they can cause.

Vaxin's technology also has applications for animal health uses. Automated in ovo (in the egg) vaccination is the method of choice for the mass immunization of poultry because of the ease of administration and lower costs. Unlike most technologies that have been tried, Vaxin's technology provides the ability to administer a protective vaccine in ovo without harming the embryo.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking 3 statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

###